Background
==========

Familial Mediterranean fever (FMF) is an inherited disease characterized by recurrent attacks of serositis, fever, and erysipelas-like skin rash \[[@b1-medscimonit-20-1578]\]. The disease is common in Mediterranean countries, and the incidence of the disease has been reported as 1/200 in Ashkenazi Jews and 1/1000 in Turks \[[@b2-medscimonit-20-1578]\]. Colchicine treatment has been shown to be effective in preventing the development of amyloidosis and in reducing proteinuria \[[@b3-medscimonit-20-1578]\]. Subclinical inflammation can also be observed in FMF. Because it is associated with atherosclerosis, the diagnosis of subclinical inflammation has become more important \[[@b4-medscimonit-20-1578],[@b5-medscimonit-20-1578]\].

It has been suggested that thrombocyte activation has an important role in the pathogenesis of atherosclerosis in various inflammatory diseases. Platelet activation has been thought to play a triggering role in arterial disorders, and mean platelet volume (MPV) is considered a good indicator of platelet activation \[[@b6-medscimonit-20-1578]--[@b10-medscimonit-20-1578]\]. Platelet distribution width (PDW) is another indicator of platelet activation \[[@b8-medscimonit-20-1578]\]. Thus, MPV and PDW measurements may help predict the risk of atherosclerosis.

As MPV and PDW measurements are readily available diagnostic parameters, their use in evaluation of diseases that may predispose patients to atherosclerosis has become popular. A few studies have assessed the role of MPV in prediction of atherosclerosis risk in FMF patients \[[@b11-medscimonit-20-1578]--[@b17-medscimonit-20-1578]\], but they have reported contradictory results. Therefore, it was necessary to investigate the usefulness of MPV in the prediction of such a risk among a relatively large study population. Neutrophil-to-lymphocyte ratio (NLR) may serve as a marker of subclinical inflammation in patients with FMF \[[@b18-medscimonit-20-1578],[@b19-medscimonit-20-1578]\].

In this study, we aimed to investigate whether MPV and PDW could be used as parameters for prediction of atherosclerosis risk in FMF patients, and if NLR might be helpful in the diagnosis of subclinical inflammation of FMF.

Material and Methods
====================

Patients diagnosed with FMF according to Tel-Hashomer criteria \[[@b19-medscimonit-20-1578]\] and who had started colchicine therapy were included in the study. Age- and sex-matched healthy subjects were also included as a control group. Patients with any other systemic disease were excluded. The study population consisted of 75 FMF cases (42 F, 33 M) with an inflammatory attack encountered within the study period, 157 attack-free patients (84 F, 73 M), and 77 (39 F, 38 M) healthy controls. The diagnosis of FMF attack was based on clinical (fever, abdominal pain, skin rash, arthritis, pleuritis) and laboratory (erythrocyte sedimentation rate (ESR) \>20 mm/h and C-reactive protein (CRP) \>5 mg/l) findings. Consecutive episodes with an interval of at least 10 days were accepted as separate attacks. White blood cell (WBC) count, platelet count, neutrophil count, lymphocyte count, NLR (absolute neutrophil-to-absolute lymphocyte ratio), MPV, PDW, CRP, ESR values, MEFV mutations, and demographic features of the patients were recorded. WBC and platelet counts, MPV and PDW values, and the demographic data of the control group were also noted. Standard EDTA-containing tubes were used for complete blood counts. All blood samples were studied in the same regularly checked analyzer (Abbott CELL-DYN 3700, United States). The study was approved by the local ethics committee.

Statistical analysis
--------------------

The data were evaluated using SPSS (Statistical Package for Social Sciences) 18.0 program for Windows. Kolmogorov-Smirnov and Shapiro-Wilk tests were used to assess whether the data were distributed normally. Numerical variables with normal distribution are shown as mean ± standard deviation and these values were compared using either the t test or 1-way ANOVA test. The comparison of the groups with abnormally distributed numerical data was performed with Mann-Whitney U test or Kruskal-Wallis test. Chi-square test was used to compare categorical variables between independent groups. Correlations between parameters with normal and abnormal distribution were computed through Pearson's and Spearman's correlation analysis, respectively.

Results
=======

A total of 75 (42 F, 33 M) FMF patients with attack, 157 (84 F, 73 M) FMF patients without attack, and 77 (39 F, 38M) healthy controls were included in the study. The patient's last-visit data were collected using an electronic patient database. Mean ages were 8.4±3.5 in the attack group, 9.1±3.6 in the attack-free group, and 8.3±3.5 in the healthy control group. Age and sex distribution did not differ statistically between the groups. There was no amyloidosis in any patients. Dose of colchicine used ranged between 0.5 and 2 mg. Leucocyte count was higher than normal 27 (36%) in the attack groups and 6 (3.8%) in attack-free groups. Thrombocyte count was higher than normal value in 61 (81.3%) attack group subjects and 10 (6.4%) attack-free subjects. CRP value was higher than normal in 20 (26.7%) attack group patients and 5 (3.2%) in the attack-free groups. ESR value higher than normal value in 58 (77.3%) and not detected in any of the patients in the attack-free group. When attack and attack-free groups were compared in terms of number of patients who were homozygous, compound heterozygous or heterozygous, there were not any statistically significant differences between groups (p=0.10). There were no significant differences between patients in the attack and attack-free groups in terms of 1-allele or 2-allele mutations (p=0.09).

Mean ESR, CRP value, and platelet count were higher in the attack group than in the attack-free group (p\<0.001, p\<0.001, p=0.002, respectively) ([Table 1](#t1-medscimonit-20-1578){ref-type="table"}). However, there were no statistically significant differences among the attack, attack-free, and control groups in terms of mean MPV and PDW value (p=0.25, p=0.96) ([Table 1](#t1-medscimonit-20-1578){ref-type="table"}).

Mean NLR value was higher in the attack group than in the attack-free group and control group (p\<0.001, p\<0.001, respectively) ([Table 1](#t1-medscimonit-20-1578){ref-type="table"}). No significant difference was found between the attack-free group and control group (p=0.76) ([Table 1](#t1-medscimonit-20-1578){ref-type="table"}).

A positive correlation was found between the MPV and PDW in the attack group and the attack-free group (r=0.61, p\<0.001 and r=0.66, p\<0.001, respectively). A negative correlation was found between platelet counts and MPV in the attack group and the attack-free group (r=−0.36, p=0.001and r=−0.32, p\<0.001, respectively). A negative correlation also was found between platelet count and PDW in the attack group and the attack-free group (r=−0.33, p=0.003, r=−0.22, p=0.007, respectively).

Discussion
==========

FMF is a chronic inflammatory disease. Outcomes of clinical and subclinical inflammation are unclear during FMF attack and in the attack-free period. As in other clinical entities accompanied by inflammation, FMF patients are at an increased risk of atherosclerosis development \[[@b6-medscimonit-20-1578],[@b12-medscimonit-20-1578],[@b13-medscimonit-20-1578]\].

Previous studies have investigated associations between MPV and atherosclerosis, myocardial infarction (MI), post-MI prognosis, post-percutaneous coronary intervention outcome, stent thrombosis, in-stent restenosis, stroke, venous thromboembolism, Behçet's diseases with venous thrombosis, gestational diabetes, preeclampsia, rheumatoid arthritis, ankylosing spondylitis, psoriasis, disease activity in ulcerative colitis, subclinical hypothyroidism, celiac disease, and von Willebrand factor in impaired glucose intolerance and in hepatitis B infection \[[@b8-medscimonit-20-1578],[@b21-medscimonit-20-1578],[@b22-medscimonit-20-1578]\].

Hormonal and immune system agents, including thrombopoietin, granulocyte-macrophage colony-stimulating factor, interleukin-1, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), affect maturation of thrombopoietic cells and the release of platelets into circulation \[[@b6-medscimonit-20-1578]\]. Increased IL-6 and TNF-α were shown in FMF patients during attack and in the attack-free period \[[@b4-medscimonit-20-1578]\]. MPV is an easily available parameter related with thrombocyte activation, which does not require additional cost. Thrombocyte activation is associated with increased risk of atherothrombosis \[[@b6-medscimonit-20-1578],[@b7-medscimonit-20-1578]\].

There is limited data concerning the relationship between MPV and atherosclerosis risk in FMF patients \[[@b11-medscimonit-20-1578]--[@b17-medscimonit-20-1578]\]. However, results of previous studies are controversial. While higher MPV values have been reported in some of these studies, others have found lower MPV values in attack and attack-free periods of FMF patients compared with the control groups. Furthermore, higher MPV values have been found in the controls and the attack-free period compared with the attack period of patients ([Table 2](#t2-medscimonit-20-1578){ref-type="table"}) \[[@b11-medscimonit-20-1578]--[@b13-medscimonit-20-1578],[@b15-medscimonit-20-1578]\]. Also, MPV was higher in the attack-free group than the control group in a study consisting of pediatric and adult patients. In the same study population, adults had higher MPV values compared to children \[[@b17-medscimonit-20-1578]\].

Amyloidosis is a serious complication of FMF, leading to end-organ damages. MPV was significantly lower in FMF patients with amyloidosis than in patients without amyloidosis and in control subjects. In addition, FMF patients without amyloidosis had higher MPV values than healthy controls in the same study \[[@b16-medscimonit-20-1578]\]. However, the results of these studies are controversial in terms of relation of MPV and FMF.

In our study, MPV was comparable between FMF patients with attack, patients in attack-free period, and healthy controls. Our results do not support any of the previous studies reporting MPV as being higher or lower in FMF patients compared to healthy subjects. There was no relationship between MPV and FMF disease in our study population.

On the other hand, PDW is another marker thought to be related with inflammation and atherothrombotic events. PDW indicates thrombocyte activity like MPV. Our study groups had similar PDW and MPV values. We suggest that MPV and PDW values are not affected by inflammation in childhood FMF. All of our study population was under colchicine treatment, which might reduce inflammation and result in lack of significant difference in MPV and PDW values between FMF patients and healthy controls.

FMF patients have higher NLR values, an inflammatory marker, than healthy controls \[[@b18-medscimonit-20-1578],[@b19-medscimonit-20-1578]\]. In the present study, we found higher NLR in the FMF attack group than in the attack-free FMF patients and healthy controls, and the latter 2 groups had similar NLR values. Neutrophil count increases during the FMF attack period due to neutrophil shift. It was higher in the attack group compared to the attack free and control groups but lymphocyte count was similar among all 3 groups. Thus, the difference in NLR was due to the difference in neutrophil count between groups. These results suggest that NLR may indicate FMF attack, but NLR cannot be used as a subclinical inflammation marker.

Platelet count, ESR, CRP, and WBC were higher in the attack group than in the attack-free patients and healthy controls, as expected.

MPV was positively correlated with PDW, and it was negatively correlated with platelet count in FMF patients of our study population. Our results are consistent with a study by Sahin et al., performed with FMF patients with attack, and another study by Makay et al. with attack-free FMF patients \[[@b11-medscimonit-20-1578],[@b13-medscimonit-20-1578]\]. MPV was reported as negatively correlated with platelet count in patients with coronary artery disease and in healthy persons \[[@b23-medscimonit-20-1578],[@b24-medscimonit-20-1578]\]. Our results suggest that inflammatory process in FMF does not affect platelet volume. On the other hand, it has been reported that large platelets are consumed during the serosal inflammation in patients with FMF \[[@b6-medscimonit-20-1578]\]. This may be another explanation for this inverse correlation.

The cross-sectional design of our study was the main limitation. Also, our study group consisted of a Turkish population and was performed only in 1 center. Thus our results may not be extrapolated to all of the FMF population.

Conclusions
===========

In conclusion, we found no difference in MPV and PDW values between FMF patients and healthy controls, while NLR was higher in FMF patients in the attack period than in FMF patients in attack-free period and healthy controls. Our results suggest that MPV and PDW values do not predict atherosclerosis risk in FMF children, and NLR may be an indicator for attack period but not attack-free period.
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###### 

Comparison of patient characteristics during attack and attack-free period and the controls.

                             During FMF attack\* (n=75)   Attack free period\*\* (n=157)   Controls\*\*\* (n=77)   p
  -------------------------- ---------------------------- -------------------------------- ----------------------- ----------------------------------------------------------
  Male/female                33/42                        73/84                            38/39                   \*^,^\*\* NS, \*^,^\*\*\* NS, \*\*^,^\*\*\* NS
  Age, years                 8.4±3.5                      9.1±3.6                          8.3±3.5                 \*^,^\*\* NS, \*^,^\*\*\* NS, \*\*^,^\*\*\* NS
  ESR, mm/h                  29.3±15.4                    7.1±3.8                          No data                 \*^,^\*\* \<0.001,
  CRP, mg/dl                 31.8±37.1                    2.0±1.5                          No data                 \*^,^\*\* \<0.001,
  WBC, /mm^3^                10612±4835                   7643±1678                        7972±1483               \*^,^\*\* 0.001, \*^,^\*\*\* 0.001, \*\*^,^\*\*\* NS
  Platelet, ×10^3^/mm^3^     335±91                       302±59                           312±59                  \*^,^\*\* 0.002, \*^,^\*\*\* NS, \*\*^,^\*\*\* NS
  MPV, fl                    7.79±0.99                    7.98±1.10                        7.75±1.24               \*^,^\*\* NS, \*^,^\*\*\* NS, \*\*^,^\*\*\* NS
  PDW, %                     17.3±0.9                     17.3±1.2                         17.2±0.9                \*,\*\* NS, \*,\*\*\* NS, \*\*,\*\*\* NS
  Neutrophil count, /mm^3^   6550±4176                    3936±1244                        4082±1142               \*^,^\*\* \<0.001, \*^,^\*\*\* \<0.001, \*\*^,^\*\*\* NS
  Lymphocyte count, /mm^3^   2999±1468                    2786±913                         2920±776                \*^,^\*\* NS, \*^,^\*\*\* NS, \*\*^,^\*\*\* NS
  NLR                        2.6±2.2                      1.6±0.8                          1.8±1.3                 \*^,^\*\* \<0.001, \*^,^\*\*\* \<0.001, \*\*^,^\*\*\* NS

ESR -- erythrocyte sedimentation rate; CRP -- C-reactive protein; WBC -- white blood cell; MPV -- mean platelet volume; PDW -- platelet distribution width; NLR -- neutrophil-lymphocyte ratio.

###### 

Comparison of our results with previous studies.

                       Our study       Şahin et al. \[[@b11-medscimonit-20-1578]\]   Arıca et al. \[[@b12-medscimonit-20-1578]\]   Makay et al. \[[@b13-medscimonit-20-1578]\]   Çoban et al. \[[@b15-medscimonit-20-1578]\]
  -------------------- --------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  Number of patients                                                                                                                                                             
   Attack              75              60                                            53                                            48                                            --
   AFP                 157             120                                           64                                            63                                            35
   Controls            77              75                                            57                                            49                                            35
  Profile of patient   Pediatric       Adult                                         Pediatric                                     Pediatric                                     Adult
  MPV                  No difference   Lower in attack and AFP                       Higher in attacks and AFP                     Lower in attacks than AFP and the controls    Higher in AFP than controls
  Platelet count       No difference   Higher in attacks than AFP and the controls   Higher in attacks and AFP                     Higher in attacks than controls               No difference
  PDW                  No difference   No data                                       No data                                       No data                                       No data

MPV -- mean platelet volume; PDW -- platelet distribution width; AFP -- attack-free period.
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